Research graph
References from HDAC Inhibition Unlocks Tumor Plasticity and Enhances Immunotherapy Response in Myc-Driven Small Cell Lung Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Small-cell lung cancer
10.1038/s41572-020-00235-0 · 2021 · External reference
Advancing therapeutics in small-cell lung cancer
10.1038/s43018-025-00996-1 · 2025 · External reference
Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer
10.1016/j.ebiom.2024.105062 · 2024 · External reference
Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group
10.1200/jco.1992.10.2.282 · 1992 · External reference
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
10.1056/nejmoa1809064 · 2018 · External reference
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
10.1016/s0140-6736(19)32222-6 · 2019 · External reference
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
10.1200/jco.1999.17.2.658 · 1999 · External reference
Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032
10.1016/j.jtho.2018.10.003 · 2019 · External reference
Tarlatamab in small-cell lung cancer after platinum-based chemotherapy
10.1056/nejmoa2502099 · 2025 · External reference
Tarlatamab for patients with previously treated small-cell lung cancer
10.1056/nejmoa2307980 · 2023 · External reference
SCLC subtypes and biomarkers of the transformative immunotherapy responses
10.1016/j.jtho.2023.06.009 · 2023 · External reference
Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase II study
10.1016/j.jtho.2019.04.026 · 2019 · External reference
Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
10.1038/s41467-021-24164-y · 2021 · External reference
Molecular subtypes of primary SCLC tumors and their associations with neuroendocrine and therapeutic markers
10.1016/j.jtho.2021.08.763 · 2022 · External reference
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer
10.1016/j.drup.2024.101198 · 2025 · External reference
Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer
10.1084/jem.161.5.1135 · 1985 · External reference
Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer
10.1016/j.semcancer.2022.02.018 · 2022 · External reference
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
10.1186/s40164-022-00356-0 · 2022 · External reference
Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma
10.1158/1078-0432.ccr-17-0741 · 2017 · External reference
MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition
10.1016/j.ccell.2016.12.005 · 2017 · External reference
Extrachromosomal DNA amplification contributes to small cell lung cancer heterogeneity and is associated with worse outcomes
10.1158/2159-8290.cd-22-0796 · 2023 · External reference
Simulation-based comprehensive benchmarking of RNA-seq aligners
10.1038/nmeth.4106 · 2017 · External reference
Fast and accurate short read alignment with Burrows-Wheeler transform
10.1093/bioinformatics/btp324 · 2009 · External reference
Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes
10.21037/tlcr.2018.02.02 · 2018 · External reference
The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression
10.1186/s13073-020-00783-w · 2020 · External reference
Profiling tumor infiltrating immune cells with CIBERSORT
10.1007/978-1-4939-7493-1_12 · 2018 · External reference
Inference of immune cell composition on the expression profiles of mouse tissue
10.1038/srep40508 · 2017 · External reference
Limma powers differential expression analyses for RNA-sequencing and microarray studies
10.1093/nar/gkv007 · 2015 · External reference
GSVA: gene set variation analysis for microarray and RNA-seq data
10.1186/1471-2105-14-7 · 2013 · External reference
Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities
10.1016/j.xcrm.2024.101610 · 2024 · External reference
Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance
10.1042/bst20210961 · 2022 · External reference
Tumor immune evasion through loss of MHC class-I antigen presentation
10.1016/j.coi.2023.102329 · 2023 · External reference
Immunomodulation of HDAC inhibitor entinostat potentiates the anticancer effects of radiation and PD-1 blockade in the murine lewis lung carcinoma model
10.3390/ijms232415539 · 2022 · External reference
Entinostat induces antitumor immune responses through immune editing of tumor neoantigens
10.1172/jci138560 · 2021 · External reference
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
10.1038/s41591-024-02813-1 · 2024 · External reference
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model
10.1016/s1535-6108(03)00220-4 · 2003 · External reference
Genetically-engineered mouse models of small cell lung cancer: the next generation
10.1038/s41388-023-02929-7 · 2024 · External reference
Small cell lung cancer: where do we go from here?
10.1002/cncr.29098 · 2015 · External reference
Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution
10.1002/1878-0261.12741 · 2020 · External reference
Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation
10.1016/j.jtho.2023.05.008 · 2023 · External reference
Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1
10.1007/s00262-019-02430-9 · 2019 · External reference
Expression of immunoproteasome genes is regulated by cell-intrinsic and -extrinsic factors in human cancers
10.1038/srep34019 · 2016 · External reference
Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo
10.1084/jem.190.5.617 · 1999 · External reference
Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms
10.1038/s41417-020-0183-x · 2021 · External reference
Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions
2023 · External reference
Mechanisms of histone deacetylase inhibitor-regulated gene expression in cancer cells
10.1089/ars.2014.5863 · 2015 · External reference
Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy
10.1158/1078-0432.ccr-20-3305 · 2021 · External reference
KDM6A epigenetically regulates subtype plasticity in small cell lung cancer
10.1038/s41556-023-01210-z · 2023 · External reference
